alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 9,201–9,225 of 10,985 studies · free to read (page 369 of 440) · 27,380 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

The effect of socioeconomic status on the severity of behavioral and psychological symptoms of dementia and ADRD caregiver outcomes: a preliminary exploration

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Alzheimer s & Dementia 2025-12-01

The ANCOVA demonstrated no significant overall differences in BPSD severity related to SES measures. 5 key findings →

Participants: 144 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Clopidogrel Use and Early Outcomes Among Older Patients Receiving a Drug-Eluting Coronary Artery Stent

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Circulation Cardiovascular Quality and Outcomes 2011-12-07

This study was a retrospective analysis of administrative data (20% sample) of 15 996 Medicare Part D enrollees who received a DES in 2006 to 2007. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Screening for the Spectrum of Cognitive Impairment in Primary Care: Development of a Machine Learning Informed, Workflow‐Friendly Care Model

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Alzheimer s & Dementia 2024-12-01

In the testing cohort, the super learner obtained a concordance statistic (95% confidence interval) of 0.822 (0.810, 0.835), higher than any of the individual ML models (Figure 1), and its predicted risk aligned with observed risk in calibration slope plots (Figure 2). 2 key findings →

Participants: 75 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Medicare Plan Switching Among Assisted Living Residents: The Role of Memory Care

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Innovation in Aging 2025-12-01

These findings suggest that moving to an AL influences Medicare enrollment decisions; and, variation in switching exists between the type of AL (general vs memory care) and whether or not an individual has dementia. 4 key findings →

Participants: 63,395 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Medicare Plan Switching Among Assisted Living Residents: The Role of Memory Care

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Innovation in Aging 2025-12-01

These findings suggest that moving to an AL influences Medicare enrollment decisions; and, variation in switching exists between the type of AL (general vs memory care) and whether or not an individual has dementia. 4 key findings →

Participants: 63,395 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Association of residential neighborhood disadvantage with amyloid PET positivity among cognitively impaired individuals

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Alzheimer s & Dementia Behavior & Socioeconomics of Aging 2026-01-29

Residence in the most disadvantaged neighborhoods may be associated with lower amyloid pathology in cognitively impaired individuals. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Both Targeted Mass Spectrometry and Flow Sorting Analysis Methods Detected the Decreased Serum Apolipoprotein E Level in Alzheimer's Disease Patients

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Molecular & Cellular Proteomics 2013-12-08

Apolipoprotein E (ApoE) polymorphism has been appreciated as a valuable predictor of Alzheimer disease (AD), and the associated ε4 allele has been recognized as an indicator of susceptibility to this disease. 4 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

O4–04–05: Geographical variation in dementia prevalence in Swedish twins: Using Bayesian inference to separate genetic and environmental effects

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Alzheimer s & Dementia 2013-07-01

There is evidence of geographical variation in dementia[1], not all of which can be ascribed to genetic factors[2]. 1 key finding →

Participants: 568 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The association of neighborhood deprivation with sleepiness among cognitively normal older adults with and without subjective cognitive decline

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Alzheimer s & Dementia 2025-12-01

Among the study population at large, there was a statistically significant association between ADI and ESS scores (β = 0.490, 95% CI [0.138, 0.842], p = 0.007). 5 key findings →

Participants: 81 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Interaction between DNA methylation and neighborhood disadvantage may impact risk for cognitive decline among Mexican Americans enrolled in the Health and Aging Brain Study – Health Disparities (HABS‐HD) Cohort

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Alzheimer s & Dementia 2023-12-01

The lack of significant results for moderation effects of the targeted epigenetic markers in our pilot study were likely due to the small sample size. 5 key findings →

Participants: 812 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Agricultural pesticide use and Alzheimer’s disease dementia prevalence across US counties in a mixed supervised–unsupervised analysis

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Scientific Reports 2026-06-11

Agricultural pesticide use represents one of the most geographically patterned environmental systems, yet most prior research has focused largely on individual compounds rather than correlated exposure regimes. 3 key findings →

Design: cross-sectional Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Characterizing Exposure to Traffic‐Related Air Pollution in a Diverse Alzheimer’s Disease Research Center Cohort

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Alzheimer s & Dementia 2024-12-01

Preliminary analysis indicates significant differences in location, ethnoracial background, ADI, and TRAP exposure amongst UCD ADRC participants. 5 key findings →

Participants: 985 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Does Neighborhood Disadvantage Moderate the Relationship between Apolipoprotein E Status and Cognitive Functioning?

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Alzheimer s & Dementia 2025-12-01

Environmental factors like neighborhood disadvantage are also associated with cognitive decline, however, few studies have integrated this with APOE research. 5 key findings →

Participants: 190 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Combination of Aβ40, Aβ42, and Tau Plasma Levels to Distinguish Amyloid-PET Positive Alzheimer Patients from Normal Controls

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Experimental Neurobiology 2025-02-28

Alzheimer disease (AD) diagnosis is confirmed using a medley of modalities, such as the detection of amyloid-β (Aβ) neuritic plaques and neurofibrillary tangles with positron electron tomography (PET) or the appraisal of irregularities in cognitive function with examinations. 3 key findings →

Participants: 53 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Storage-dependent variability in Alzheimer disease-related plasma biomarker results using the Fujirebio Lumipulse G1200 platform

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Journal of Neuropathology & Experimental Neurology 2025-09-17

Alzheimer disease plasma biomarkers have emerged as minimally invasive, cost-effective tools for early diagnosis and disease monitoring yet their stability under common "real world" pre-analytical conditions remains incompletely characterized. 3 key findings →

Participants: 12 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Development of a novel in‐house blood biomarker panel for early diagnosis of Alzheimer’s disease

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Alzheimer s & Dementia 2025-12-01

We have successfully generated specific high affinity monoclonal antibodies against p -Tau217, p -Tau205, and N-terminus GFAP and have confirmed that these antibodies have the necessary specificity and sensitivity for the Simoa platform. 2 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

ApoE4 Upregulates GSK ‐3β to Aggravate Alzheimer‐Like Pathologies and Cognitive Impairment in Type 2 Diabetic Mice

✓ Peer-reviewed alzhub usefulness score 39 out of 100. CNS Neuroscience & Therapeutics 2025-09-01

We observed that GSK-3β activity was significantly upregulated in ApoE4 mice, accompanied by disruption of the insulin signaling pathway. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed